Anteris Technologies Secures CMS Reimbursement Supporting U.S. Site Activation for PARADIGM Trial

Anteris Technologies Global Corp. has attained U.S. Medicare reimbursement eligibility for the PARADIGM Trial, facilitating U.S. site activation under a CMS national coverage policy. The trial will compare the safety and effectiveness of the DurAVR® Transcatheter Heart Valve against commercially available TAVRs. It aims to enroll approximately 1000 patients and assess non-inferiority on key health outcomes at one year post-procedure.